论文部分内容阅读
目的探讨血清中乳酸脱氢酶(LDH)、β2微球蛋白(β2-MG)以及CA125定量检测对非霍奇金淋巴瘤诊断及预后的价值。方法回顾分析64例经病理确诊的非霍奇金淋巴瘤患者的LDH、β2–MG和CA125,判断其与临床分期、分组及治疗效果的关系。结果非霍奇金淋巴瘤患者LDH、β2-MG和CA125活性明显高于对照组(P<0.01)。Ⅰ～Ⅱ期与Ⅲ～Ⅳ期、无全身症状组(A组)与有全身症状组(B组)以及IP(I0～2分)组与(3～5分)组相比,后者明显高于前者,差异具有显著性(P<0.01)。LDH、β2–MG和CA125活性均未增高组的缓解率和3年生存率明显高于均增高组(P<0.05)。结论联合检测LDH、β2–MG和CA125血清水平可作为非霍奇金淋巴瘤的分期及预后的评估指标。
Objective To investigate the value of quantitative detection of serum lactate dehydrogenase (LDH), β2-microglobulin (β2-MG) and CA125 in the diagnosis and prognosis of non-Hodgkin’s lymphoma. Methods The LDH, β2-MG and CA125 levels in 64 patients with non-Hodgkin’s lymphoma confirmed by pathology were retrospectively analyzed to determine the relationship between LDH, β2-MG and CA125 in clinical stage, grouping and treatment outcome. Results The activities of LDH, β2-MG and CA125 in patients with non-Hodgkin’s lymphoma were significantly higher than those in the control group (P <0.01). Compared with the group of systemic symptoms (group B), the group of IP (group I0 ~ 2) and the group of (3-5), there was a significant difference between group Ⅰ ~ Ⅱ and group Ⅲ ~ Ⅳ Higher than the former, the difference was significant (P <0.01). The remission rate and 3-year survival rate of the patients with no increase of LDH, β2-MG and CA125 activity were significantly higher than those of the control group (P <0.05). Conclusions Combined detection of serum LDH, β2-MG and CA125 levels can be used as an index to evaluate the staging and prognosis of non-Hodgkin’s lymphoma.